Phase 3 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People whose immune system is weakened — this includes conditions or treatments such as HIV, organ transplants, certain cancers (including blood cancers), bone marrow transplants, autoimmune or systemic diseases, chemotherapy, long-term steroid use, immunosuppressive medications, or inherited immune deficiencies
- People who have attended a day hospital or emergency department, or who have been admitted to hospital
- People who have a confirmed or likely diagnosis of a lung infection called PCP (Pneumocystis pneumonia), based on specific diagnostic criteria used by the trial
Who may not be able to join:
- People who have had a serious allergic or harmful reaction to the antibiotic TMP-SMX (also known as trimethoprim-sulfamethoxazole), any sulfa-based drug, or any ingredient in the medication being studied
- People who have been consistently taking TMP-SMX as a preventive treatment for PCP for 4 weeks or more at the time of enrolment
- People who have already received more than 96 hours (4 days) of any treatment for PCP before joining the trial
- People with significant liver problems, specifically where a liver enzyme called alanine aminotransferase is measured at 5 or more times the normal upper limit
- People who have a condition called G6PD deficiency (a genetic enzyme disorder affecting red blood cells)
- People who have a condition called porphyria (a group of disorders affecting the nervous system or skin)
- People who are known to be pregnant or breastfeeding (as noted by Health Canada guidelines)
- People who are unable to give informed consent themselves and do not have a healthcare proxy available to do so on their behalf; people who have declined to give consent; or people who cannot be reliably contacted outside of hospital (for example, by phone, email, or text message
- People who have previously taken part in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Emily G McDonald, MD MSc, Research Institute of the McGill University Health Centre
Phone: 514-934-1934
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Hierarchical composite outcome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.